Cat. No.: HY-10082

Triapine

(Synonyms: 3-AP; PAN-811; OCX191)

11 Cited Publications

Customer Review

Based on 11 publication(s) in Google Scholar

Triapine (3-AP; PAN-811) is a potent inhibitor of the M2 subunit of ribonucleotide reductase (RR), and is a potent radiosensitizer.

For research use only. We do not sell to patients.

Purity: 99.78%
CAS No.: 143621-35-6
Formula: C₇H₉N₅S
Molecular Weight:195.24

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Triapine Chemical Structure

CAS No.: 143621-35-6

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (11)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Triapine (3-AP; PAN-811) is a potent inhibitor of the M2 subunit of ribonucleotide reductase (RR), and is a potent radiosensitizer.

IC₅₀ & Target

Ribonucleotide reductase (RR)^[1]

All DNA/RNA Synthesis Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	0.7 μM Compound: Triapine	Cytotoxicity against human A2780 cells incubated for 72 hrs by MTT assay Cytotoxicity against human A2780 cells incubated for 72 hrs by MTT assay	[PMID: 27336684]
A549	IC₅₀	2.288 μM Compound: 3-AP	Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 32438199]
BGC-823	IC₅₀	3.07 μM Compound: 3-AP	Antiproliferative activity against human BGC-823 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human BGC-823 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 32438199]
EC9706	IC₅₀	3.084 μM Compound: 3-AP	Antiproliferative activity against human EC9706 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human EC9706 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 32438199]
GES1	IC₅₀	5.4 μM Compound: 3-AP	Cytotoxicity against human GES-1 cells after 72 hrs by MTT assay Cytotoxicity against human GES-1 cells after 72 hrs by MTT assay	[PMID: 30108734]
GES1	IC₅₀	5.6 μM Compound: 3-AP	Antiproliferative activity against human GES-1 cells assessed as reduction in cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human GES-1 cells assessed as reduction in cell proliferation incubated for 72 hrs by MTT assay	[PMID: 31614257]
GES1	IC₅₀	6.103 μM Compound: 3-AP	Cytotoxicity against human GES1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human GES1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32438199]
HCT-116	IC₅₀	1.226 μM Compound: II	Dark cytotoxicity against human HCT116 cells expressing wild type p53 after 96 hrs by MTT assay Dark cytotoxicity against human HCT116 cells expressing wild type p53 after 96 hrs by MTT assay	[PMID: 24900837]
HGC-27	IC₅₀	11.495 μM Compound: 3-AP	Antiproliferative activity against human HGC-27 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HGC-27 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 32438199]
HUVEC	IC₅₀	3448 nM Compound: 3-AP	Cytotoxicity against HUVEC assessed as reduction in cell viability incubated for 48 hrs by cell-titer-Glo luminescent cell viability assay Cytotoxicity against HUVEC assessed as reduction in cell viability incubated for 48 hrs by cell-titer-Glo luminescent cell viability assay	[PMID: 30835473]
KB 3-1	IC₅₀	>800 μM Compound: 3-AP	Antiproliferative activity against human KB3-1 cells after 24 hrs by MTT assay Antiproliferative activity against human KB3-1 cells after 24 hrs by MTT assay	[PMID: 27524608]
KB 3-1	IC₅₀	>800 μM Compound: 3-AP	Antiproliferative activity against human KB3-1 cells after 24 hrs in presence of P-gp inhibitor elacridar by MTT assay Antiproliferative activity against human KB3-1 cells after 24 hrs in presence of P-gp inhibitor elacridar by MTT assay	[PMID: 27524608]
KB 3-1	IC₅₀	1.4 μM Compound: 9	Cytotoxicity against human P-gp-negative KB-3-1 cells after 72 hrs by MTT assay Cytotoxicity against human P-gp-negative KB-3-1 cells after 72 hrs by MTT assay	[PMID: 19397322]
KB 3-1	IC₅₀	3.1 μM Compound: Triapine	Cytotoxicity against human KB-3-1 cells incubated for 72 hrs by MTT assay Cytotoxicity against human KB-3-1 cells incubated for 72 hrs by MTT assay	[PMID: 27336684]
KB-V1	IC₅₀	>800 μM Compound: 3-AP	Antiproliferative activity against human KBV1 cells over expressing P-gp after 24 hrs by MTT assay Antiproliferative activity against human KBV1 cells over expressing P-gp after 24 hrs by MTT assay	[PMID: 27524608]
KB-V1	IC₅₀	>800 μM Compound: 3-AP	Antiproliferative activity against human KBV1 cells over expressing P-gp after 24 hrs in presence of P-gp inhibitor elacridar by MTT assay Antiproliferative activity against human KBV1 cells over expressing P-gp after 24 hrs in presence of P-gp inhibitor elacridar by MTT assay	[PMID: 27524608]
KB-V1	IC₅₀	5.9 μM Compound: 9	Cytotoxicity against human P-glycoprotein-expressing KBV1 cells after 72 hrs by MTT assay Cytotoxicity against human P-glycoprotein-expressing KBV1 cells after 72 hrs by MTT assay	[PMID: 19397322]
L1210	IC₅₀	1.3 μM Compound: 1; 3-AP	Growth inhibition of mouse L1210 cells by MTS assay Growth inhibition of mouse L1210 cells by MTS assay	[PMID: 30904782]
MCF7	IC₅₀	>32 μM Compound: 3-AP	Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 32438199]
MCF7	IC₅₀	18.85 μM Compound: 3-AP	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30108734]
MES-SA	IC₅₀	1.305 μM Compound: Triapine	Cytotoxicity against human MES-SA cells transfected with mCherry fluorescent protein assessed as inhibition of cell proliferation incubated for 72 hrs by fluorescent assay Cytotoxicity against human MES-SA cells transfected with mCherry fluorescent protein assessed as inhibition of cell proliferation incubated for 72 hrs by fluorescent assay	[PMID: 27161177]
MES-SA/Dx5	IC₅₀	2.523 μM Compound: Triapine	Cytotoxicity against human MES-SA/DX5 cells transfected with mCherry fluorescent protein assessed as inhibition of cell proliferation incubated for 72 hrs by fluorescent assay Cytotoxicity against human MES-SA/DX5 cells transfected with mCherry fluorescent protein assessed as inhibition of cell proliferation incubated for 72 hrs by fluorescent assay	[PMID: 27161177]
MGC-803	IC₅₀	5.411 μM Compound: 3-AP	Antiproliferative activity against human MGC-803 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 32438199]
MGC-803	IC₅₀	9.68 μM Compound: 3-AP	Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay	[PMID: 30108734]
MV4-11	IC₅₀	967.6 nM Compound: 3-AP	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 48 hrs by cell-titer-Glo luminescent cell viability assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 48 hrs by cell-titer-Glo luminescent cell viability assay	[PMID: 30835473]
PC-3	IC₅₀	0.56 μM Compound: 3-AP	Antiproliferative activity against human PC3 cells assessed as reduction in cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as reduction in cell proliferation incubated for 72 hrs by MTT assay	[PMID: 31614257]
PC-3	IC₅₀	0.56 μM Compound: 3-AP	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 33153765]
SGC-7901	IC₅₀	18.349 μM Compound: 3-AP	Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 32438199]
SK-N-MC	IC₅₀	0.26 μM Compound: 3-AP	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay	[PMID: 17602603]
SK-N-MC	IC₅₀	0.26 μM Compound: 3-AP	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay	[PMID: 19601577]
SK-N-MC	IC₅₀	0.31 μM Compound: triapine	Antiproliferative activity against human SK-N-MC cells by MTT assay Antiproliferative activity against human SK-N-MC cells by MTT assay	[PMID: 17142046]
SK-N-MC	IC₅₀	0.54 μM Compound: 3-AP	Antiproliferative activity against human SK-N-MC cells by MTT assay Antiproliferative activity against human SK-N-MC cells by MTT assay	[PMID: 17963372]
SMMC-7721	IC₅₀	42.81 μM Compound: 3-AP	Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay	[PMID: 30108734]
SW480	IC₅₀	>50 μM Compound: Triapine	Cytotoxicity against triapine-resistant human SW480 cells incubated for 72 hrs by MTT assay Cytotoxicity against triapine-resistant human SW480 cells incubated for 72 hrs by MTT assay	[PMID: 27336684]
SW480	IC₅₀	0.84 μM Compound: Triapine	Cytotoxicity against human SW480 cells incubated for 72 hrs by MTT assay Cytotoxicity against human SW480 cells incubated for 72 hrs by MTT assay	[PMID: 27336684]
WI-38	IC₅₀	>25 μM Compound: Triapine	Cytotoxicity against human WI38 cells incubated for 72 hrs by MTT assay Cytotoxicity against human WI38 cells incubated for 72 hrs by MTT assay	[PMID: 27336684]

In Vitro

Triapine (3-AP; PAN-811) is a potent derivative of α-heterocyclic carboxaldehyde thiosemicarbazone (HCT) that inhibits hRRM2 and p53R2 isoforms of the M2 subunit^[1]. Triapine (3-AP; PAN-811) is thought to inhibit ribonucleotide reductase through its preformed iron chelate, rather than directly by removing iron from the active site. In cells containing less topoisomerase IIα fewer DNA strand breaks will be produced, and thus topoisomerase II poisons will be less inhibitory in the K/VP.5 cell line. The IC₅₀s for Dp44mT growth inhibition are 48±9 nM and 60±12 nM, for K562 and K/VP.5 cells, respectively. The IC₅₀s for Triapine growth inhibition are 476±39 nM and 661±69 nM for K562 and K/VP.5 cells, respectively^[2]. PKIH and DpT Fe chelators show high antiproliferative activity against a range of tumor cell lines. Dp44mT shows the greatest antitumor efficacy with an IC₅₀ that ranged from 0.005 to 0.4 μM. The average IC₅₀ of Dp44mT over 28 cell types is 0.03±0.01 μM, which is significantly lower than that of Triapine (3-AP; PAN-811; average IC₅₀: 1.41±0.37 μM)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Triapine (3-AP; PAN-811) causes a significant increase (1.7-fold) in splenic weight when expressed as a percentage of total body weight (1.02±0.06%; n=25) compared with control mice (0.6±0.03%; n=27). In the long-term group, a significant increase in heart weight is observed after Dp44mT (0.4 mg/kg per day) (0.8±0.06%; n=4) compared with control mice (0.5±0.01%; n=6). A significant decrease in the expression of Ndrg1, TfR1, and VEGF1 in the liver is noted for Dp44mT- and Triapine (12 mg/kg per day)-treated animals. The decreased expression could be related to the increased liver Fe in both Dp44mT- and Triapine-treated mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 143621-35-6
Appearance Solid
Molecular Weight 195.24
Formula C₇H₉N₅S
Color Light yellow to khaki
SMILES

S=C(N)N/N=C/C1=NC=CC=C1N
Synonyms

3-AP; PAN-811; OCX191
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (11)

All

Sort by:

Journal Impact Factor

Nature

Lithocholic acid phenocopies anti-ageing effects of calorie restriction. [Abstract]

2025 Jul;643(8070):192-200. PMID: 39695227
Cell Death Dis

RRM1 inhibition sensitizes lung adenocarcinoma to decitabine treatment. [Abstract]

2026 Feb 26;17(1):275. PMID: 41748545
Cancer Lett

Inhibition of Ribonucleotide Reductase Subunit M2 Enhances the Radiosensitivity of Metastatic Pancreatic Neuroendocrine Tumor. [Abstract]

2024 Aug 1:596:216993. PMID: 38801884
JACS Au

DefNEtTrp: An Iron Dual Chelator Approach for Anticancer Application. [Abstract]

2024 Dec 4;4(12):4799-4808. PMID: 39735911
mBio

Blockade of de novo dNTP biosynthesis pathway delays HIV-1 early life cycle kinetics and dynamics. [Abstract]

2025 Aug 13;16(8):e0104725. PMID: 40586616
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
J Cancer Res Clin Oncol

Synergistic anticancer activity of combined ATR and ribonucleotide reductase inhibition in Ewing's sarcoma cells. [Abstract]

2023 Sep;149(11):8605-8617. PMID: 37097390
Res Sq

2026 Jun 17.
Rush University

2025.
Res Sq

2025 Mar 26.
Research Square Preprint

2023 Jun 9.

Solvent & Solubility

In Vitro:

DMSO : ≥ 47 mg/mL (240.73 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.1219 mL

25.6095 mL

51.2190 mL

5 mM

1.0244 mL

5.1219 mL

10.2438 mL

10 mM

0.5122 mL

2.5610 mL

5.1219 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (12.80 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (12.80 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[2]

An MTT assay is used to determine cell growth inhibition of CHO cells. Human leukemia K562 cells and K/VP.5 cells (a 26-fold etoposide-resistant K562-derived sub-line with decreased levels of topoisomerase IIα mRNA and protein) are maintained as suspension cultures in MEM containing 10% fetal calf serum (FCS). For growth inhibition assays, K562 and K/VP.5 cells are plated at a concentration of 1.5×10⁵ cell/mL, and incubated 5 d with various concentrations of Dp44mT, Triapine or vehicle (DMSO) for 48 h, after which cells are counted on a model ZBF Coulter counter. The IC₅₀ growth inhibitory concentration for each cell line is calculated from a non-linear least-squares fit to a 2-parameter logistic equation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[3]

Mice^[3]
Female BALB/c nu/nu mice are used at 8-10 weeks of age. Tumor cells in culture are harvested, and 10⁷ cells are suspended in Matrigel and injected s.c. into the right flanks of mice. After engraftment, tumor size is measured by Vernier calipers. Tumor volumes (in cubic millimeters) are calculated. When tumor volumes reached 120 mm³, i.v. treatment began (day 0). Chelators (e.g., Triapine) are dissolved in 15% propylene glycol in 0.9% saline and injected i.v. over 5 consecutive days per week for up to 7 weeks. Control mice are treated with vehicle alone.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (420 KB)
- English - EN (420 KB)
- Français - FR (420 KB)
- Deutsch - DE (420 KB)
- Norwegian - NO (420 KB)
- Español - ES (420 KB)
- Swedish - SV (420 KB)
- Italian - IT (420 KB)
- Korean - KR (420 KB)
- Portuguese - PT (420 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Martin LK, et al. A dose escalation and pharmacodynamic study of Triapine and radiation in patients with locally advanced pancreas cancer. Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):e475-81. [Content Brief]

[2]. Yalowich JC, et al. The anticancer thiosemicarbazones Dp44mT and Triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase IIα. Biochem Pharmacol. 2012 Jul 1;84(1):52-8. [Content Brief]

[3]. Whitnall M, et al. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14901-6. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	5.1219 mL	25.6095 mL	51.2190 mL	128.0475 mL
	5 mM	1.0244 mL	5.1219 mL	10.2438 mL	25.6095 mL
	10 mM	0.5122 mL	2.5610 mL	5.1219 mL	12.8048 mL
	15 mM	0.3415 mL	1.7073 mL	3.4146 mL	8.5365 mL
	20 mM	0.2561 mL	1.2805 mL	2.5610 mL	6.4024 mL
	25 mM	0.2049 mL	1.0244 mL	2.0488 mL	5.1219 mL
	30 mM	0.1707 mL	0.8537 mL	1.7073 mL	4.2683 mL
	40 mM	0.1280 mL	0.6402 mL	1.2805 mL	3.2012 mL
	50 mM	0.1024 mL	0.5122 mL	1.0244 mL	2.5610 mL
	60 mM	0.0854 mL	0.4268 mL	0.8537 mL	2.1341 mL
	80 mM	0.0640 mL	0.3201 mL	0.6402 mL	1.6006 mL
	100 mM	0.0512 mL	0.2561 mL	0.5122 mL	1.2805 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Triapine

Anti-COVID-19 Compound Library

Anti-Pancreatic Cancer Compound Library

Targeted Diversity Library

Anti-Prostate Cancer Compound Library

Heterocyclic Compound Library

Cysteine Targeted Covalent Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Publications Citing Use of MedChemExpress (MCE) Triapine

All DNA/RNA Synthesis Isoforms

Biological Activity

Chemical Information

Publications (11)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Triapine

Anti-COVID-19 Compound Library

Anti-Pancreatic Cancer Compound Library

Targeted Diversity Library

Anti-Prostate Cancer Compound Library

Heterocyclic Compound Library

Cysteine Targeted Covalent Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Publications Citing Use of MedChemExpress (MCE) Triapine

All DNA/RNA Synthesis Isoforms

Biological Activity

Chemical Information

Publications (11)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Triapine Related Classifications

HY-10082 Related Classifications